The revenue beat and raised guidance are positive fundamental signals, but the GAAP net loss from impairment may weigh on near-term sentiment. The merger with Indivior adds a strategic premium and creates a larger CNS platform; traders should monitor the joint proxy statement for exchange ratio details and regulatory approvals. Focus on non-GAAP adjusted operating earnings as the clean measure of underlying performance.
Price Chart
Executive Summary
Supernus Pharmaceuticals reported Q2 2026 total revenues of $219.1M (+32% YoY), beating consensus of $205.4M, but GAAP net loss of $58.4M ($1.01 loss per share) missed the $0.30 consensus due to a $54.9M non-cash intangible impairment charge for APOKYN. The company raised full-year 2026 revenue guidance to $860M-$890M and adjusted operating earnings guidance to $150M-$180M, while simultaneously announcing an all-stock merger of equals with Indivior Pharmaceuticals. The combination of a revenue beat, raised guidance, and a transformative merger creates a significant but mixed catalyst.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues $219.1M vs consensus $205.4M (beat by 6.7%), up 32% YoY
- GAAP diluted EPS of ($1.01) vs consensus $0.30 (miss), driven by $54.9M APOKYN impairment
- Qelbree net sales $89.2M (+15% YoY), ZURZUVAE collaboration revenue $35.4M, ONAPGO $13.5M
- Full-year 2026 revenue guidance raised to $860M-$890M (from $840M-$870M)
- Full-year adjusted operating earnings guidance raised to $150M-$180M (from $140M-$170M)
- Announced all-stock merger of equals with Indivior Pharmaceuticals, creating a diversified CNS company
Financial Impact
Revenue beat of ~$13.7M vs consensus; GAAP EPS miss of $1.31 vs consensus; guidance raises imply ~$20M increase in revenue midpoint and ~$10M increase in adjusted operating earnings midpoint
Risk Factors
- Merger execution risk: shareholder approvals, regulatory clearances, and potential termination fees
- APOKYN impairment ($54.9M) signals declining product value; further impairments possible
- Legacy products Trokendi XR, Oxtellar XR, and APOKYN continue to decline (down 25%, 25%, 51% YoY respectively)
- Integration of Indivior's business could distract from commercial execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001356576-26-000035 |
| Document: supn-20260803.htm | 0001356576-26-000035 |
| Document: 0001356576-26-000035-index-headers.html | 0001356576-26-000035 |
| Document: 0001356576-26-000035-index.html | 0001356576-26-000035 |
| Document: 0001356576-26-000035.txt | 0001356576-26-000035 |
| 8-K Data (Synthetic) | 0001356576-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.41 (+2.22%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.41 (−1.94%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.41 (−1.94%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.41 (−7.80%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.41 (−7.80%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.41 (−7.80%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.41 (−7.80%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.41 (−10.13%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.41 (−10.13%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.41 (−10.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access